Skip to content

Contributions of Health Psychology to Support Patients With Diabetes Through Online Tools

Development of an E-program to Improve the Quality of Life of People With Diabetes Based on Acceptance and Commitment Therapy (ACT)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06194240
Acronym
DiabACT
Enrollment
300
Registered
2024-01-08
Start date
2021-09-01
Completion date
2023-06-06
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

With over 4 million people living with diabetes in France, i.e. 6% of the general population, it is necessary to consider both their physical and mental health. Indeed, recent studies have shown that with a good quality of life, patients have better disease management, improved physical health and social life, and reduced anxiety and depressive symptoms. Quality of life is at the heart of this research project. In order to improve it, several psychotherapies can be used, notably those that include mindfulness. Of all those proposed in the literature, Acceptance and Commitment Therapy (ACT), developed by Hayes, appears to be ideally suited to this objective. The aim of this psychotherapy is to improve the patient's psychological flexibility. According to the scientific literature, ACT therapy has been shown to improve the quality of life of patients living with diabetes, as well as their ability to manage their condition and reduce anxiety and depressive symptoms. This research project aims to: 1. To help patients cope better with their illness through learning the different dimensions of ACT therapy in order to obtain a toolbox to use on a daily basis, when necessary. 2. To offer professionals alternatives to the traditional care of diabetic patients with the toolbox cited above. 3. To enable health authorities to take advantage of this program and these different exercises to reduce complications in the medium and long term for people with diabetes and change health behaviors. In 2020, the French Diabetics Federation created the Slow Diabetes movement. The initial objective of which was to help people with diabetes to better cope with their isolation linked to the Covid-19 pandemic. Since its launch, this movement has taken the form of several programs lasting three or six weeks and developed to improve the general well-being of people with diabetes. The research proposed here seeks to improve the quality of life of diabetic patients through online ACT therapy, based on the Slow Diabetes model.

Detailed description

The aim of this detailed description is to present the research protocol of a controlled randomized trial to evaluate the impact of an e-program based on Acceptance and Commitment Therapy (ACT) for people living with diabetes in France on the quality of life and the psychological flexibility. The recruitment of participants is done through a call for participation launched by the French Federation of Diabetics, during which patients have access to a Patient Information Notice (PIN) presenting the project. This PIN enable diabetic patients to find out about the different possible groups of the study and the planned randomization. In this way, they will know that they can belong to three different groups : 1) The Slow ACT intervention group, which will follow an intervention based on acceptance and commitment therapy (duration 6 weeks); 2) The Slow Diabetes control group, which will follow a Slow Diabète Summer program (duration 5 weeks - launched by the French Federation of Diabetics); 3) The No program control group, which will not follow either of the two interventions, and will be able to compare the data from the two groups presented above. Finally, 15 of the people in the ACT intervention group were voluntarily recruited to a Single Case protocol. This took place over 14 weeks, with 14 measures (psychological flexibility and quality of life). The content of the e-program ACT in which not all patients have participated is sent to all of the participants of the study at the end of it, for reasons of ethics and fairness.

Interventions

BEHAVIORALDiabACT

E-program proposed to diabetic patients based on ACT therapy.

Sponsors

University of Lorraine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Participants must be aged 18 and over, * To live with type 1 diabetes (T1D) or type 2 diabetes (T2D), * Be French, * Living in France * Understand and accept the constraints of the study, * Have given their consent after having read the terms of the study, * Be affiliated to social security.

Exclusion criteria

* Lack of autonomy making it impossible to complete the online questionnaire, * Members of the Slow Diabetes group cannot have benefited from the Slow ACT program, * Persons deprived of their rights, persons under guardianship. Age, type of diabetes or gender are not inclusion criteria, but will be controlled for in the statistical analyses, along with other socio-demographic variables (i.e. level of education, socio-economic level).

Design outcomes

Primary

MeasureTime frameDescription
12-Item Short Form Health SurveyBefore the intervention and six weeks after (when the program is finished)Quality of life. The minimum score is 0 (bad quality of life) and the maximum score is 100 (good quality of life).

Secondary

MeasureTime frameDescription
Basic Psychological Need Satisfaction and Frustration ScaleBefore the intervention and six weeks after (when the program is finished)Basic psychological needs. The score is divided into six categories, according to the satisfaction or frustration of one of the three basic psychological needs. When it comes to satisfaction, the closer the score is to seven, the better it is. If the score is close to seven for frustration items, then the latter will be high.
Multidimensional Psychological Flexibility InventoryBefore the intervention and six weeks after (when the program is finished)Psychological Flexibility. This scale is divided into twelve categories, based on functional and dysfunctional processes. For functional processes, the closer the average score is to 7, the more correct is the participant's process. On the other hand, for dysfunctional processes, if the average score is close to 7, then the process is truly dysfunctional.
Hospital Anxiety and Depression ScaleBefore and after the interventionAnxiety and Depression. The total score ranges from 0 to 21 for each category (depression or anxiety). A score of 10 or more indicates definite symptomatology.
Diabetes AcceptanceBefore the intervention and six weeks after (when the program is finished)Diabetes Acceptance and Action Scale - revised. The scale is a 9-point measure of diabetes acceptance. It is based on a five-point Likert scale ranging from never true (0) to always true (4). Higher scores mean greater acceptance and greater ability to adapt to diabetes.
Generic Adherence Profile for Chronic DiseasesBefore the intervention and six weeks after (when the program is finished)Therapeutic adherence. The questionnaire consists of 32 items covering three components of health adherence: medication and/or medical adherence, lifestyle adherence and diet adherence. Some items measure non-adherence to therapy (items 2 and 6 to 16) and others measure adherence to therapy. Responses to the items were rated on a 4-point Likert-type scale (1, never, to 4, all the time).
Treatment Self-Regulation QuestionnaireBefore the intervention and six weeks after (when the program is finished)Motivation towards treatments. Two scores are given for this 19-item scale. One for autonomous motivation, with average scores ranging from 0 (no autonomous motivation) to 7 (strong autonomous motivation) with 8 items. And another for controlled motivation, with average scores ranging from 0 (no controlled motivation) to 7 (high controlled motivation) on 11 items.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026